All stories
Jump to date
Wednesday, November 11 · 6 stories
- Federal Policy
CMS Finalizes 2027 OPPS Rule With 340B, Site-Neutral Changes
CMS released its 2027 Hospital Outpatient Prospective Payment System and ASC final rule on November 4, 2026, with most provisions effective January 1, 2027. The rule finalizes a 2.3% payment update, removes 637 services from the inpatient-only list, expands the ASC covered procedures list, and sets Physician Fee Schedule-equivalent payments for certain non-contrast imaging at off-campus provider-based departments (rural sole community hospitals exempt). It also sets 340B drug payment at ASP minus 28% (instead of the proposed ASP minus 33.4%), with exemptions for rural sole community, children's and PPS-exempt cancer hospitals, and redistributes savings into higher payments for other outpatient services including radiation therapy. Separately, CMS is raising the annual reduction used to recover earlier 340B-related payments from 0.5% to 2%, expecting to complete recovery by 2031, with an exemption for hospitals certified on or after January 2, 2018; new provider-based requirements take effect January 1, 2028.
- Federal Policy
CMS Finalizes Hospital Outpatient Provider-Based Attestation Rule
In a client alert, Polsinelli reports that CMS finalized provider-based attestation requirements for off-campus hospital outpatient departments as part of the Nov. 4, 2026 Outpatient Prospective Payment Rule, implementing a requirement under Section 6225 of the Consolidated Appropriations Act, 2026. Hospitals must obtain a unique NPI for each off-campus physical location, update their 855A Medicare enrollment records, and submit attestations by Dec. 31, 2027, with no exemption for departments previously approved as provider-based. New outpatient departments beginning service after Jan. 1, 2028, must attest within the two-year period before their first service date. CMS will develop an electronic filing portal, has not yet released the standard attestation form, and will select a random sample of hospitals for extended review requiring supporting documentation within a generally 60-day window. Critical access hospitals are exempt, but certain other service lines such as laboratories and ambulance suppliers remain subject to the attestation requirement.
- Federal Policy
FDA, CMS Unveil Coordinated Moves on Individualized Gene Therapies
HHS announced coordinated actions by FDA and CMS on October 27, 2026 to advance individualized gene therapies. FDA issued draft guidance allowing companies to seek approval for multiple patient-specific versions of a genome-editing therapy under one Biologics License Application, using an "Individualized Feature Space" to define which product components may vary without separate clinical trials for each variant, limited to single-gene disorders with known pathogenic variants. CMS separately announced plans to expand its Cell and Gene Therapy Access Model, which uses outcomes-based agreements with manufacturers to improve Medicaid access, beyond its initial focus on sickle cell disease. The guidance is in draft form and does not change FDA's approval standards or existing expedited-review designations.
Tuesday, November 10 · 4 stories
- Federal Policy · ID
Idaho's Second-Year Rural Health Transformation Grant Falls to $182.7M
Federal authorities announced Monday that Idaho will receive about $182.7 million in the second year of the Rural Health Transformation Program, down from nearly $186 million in year one. The five-year, $50 billion nationwide program was created under the 2025 One Big Beautiful Bill Act, which also cut federal Medicaid spending by about $1 trillion over 10 years starting Jan. 1, 2027. Idaho's second-year award ranked 40th among states; HHS Secretary Robert F. Kennedy Jr. said the funds aim to expand rural access, strengthen the workforce and improve prevention. Idaho's first-year funds, fully awarded by Oct. 28, went to rural hospital infrastructure, emergency equipment, workforce development and mobile clinics; state officials attributed the lower ranking to Idaho's low population and provider density under federal scoring criteria.

- Federal Policy
Democratic Congress Could Reshape Drug Pricing, 340B, Medicaid Oversight
Becker's Hospital Review outlines six ways Democratic control of Congress, beginning Jan. 3, could affect pharmacy policy, while Republicans retain control until then and President Trump keeps veto power. Democrats would gain committee agenda-setting, subpoena and hearing powers to scrutinize drugmakers' pricing agreements, 340B rebate pilots and PBM practices; Sen. Ron Wyden is positioned to lead Senate Finance and Sen. Bernie Sanders is expected to chair the HELP committee. House Democrats' agenda reportedly includes restoring enhanced ACA subsidies and reversing nearly $1 trillion in Medicaid cuts, though both face veto risk. The piece also notes FDA's prescription drug user-fee authority expires in September 2027, creating a legislative vehicle for other drug policy provisions.
- Federal Policy · OR
Wyden Vows to Reverse Medicaid Cuts as Finance Chair
Senator Ron Wyden, set to chair the Senate Finance Committee after Democrats won a 54-seat majority, said Democrats will introduce legislation "immediately" in January to reverse Medicaid cuts from the 2025 tax and spending law known as H.R. 1 and to restore more generous Affordable Care Act subsidies. He specifically cited the nationwide Medicaid work requirement set to begin rolling out January 1, which in Oregon would apply to about 560,000 adults and which the state says contributes to a projected $420 million budget deficit. Wyden did not specify how Democrats would pay for restoring subsidies and coverage but suggested raising effective tax rates on the ultra-wealthy. He acknowledged that undoing H.R. 1 would be difficult and could face a presidential veto.
- Federal Policy
Sen. Kim's MediKids Bill Gains Traction in House Democrats' Agenda
Becker's Hospital Review reports that as Medicare for All drew strong polling support ahead of the 2026 midterms, House Democrats' healthcare agenda stopped short of endorsing it, instead citing a consensus push toward universal coverage with Sen. Andy Kim's "MediKids" bill gaining traction. The bill, introduced in July, would broaden Medicaid eligibility to guarantee coverage through age 26, require states to automatically enroll newborns, allow guardians to opt out if other coverage exists, and set coverage without regard to immigration status. It would set the federal medical assistance percentage at 100% for the newly eligible population, with most provisions taking effect two years after enactment. The American Academy of Pediatrics and American College of Obstetricians & Gynecologists have endorsed the bill, and a New York Times commentary noted it was designed with budget reconciliation in mind.
Monday, November 9 · 10 stories
- Federal Policy
FDA Mandates Vision Loss Warning on GLP-1 Drug Labels
The FDA issued a Nov. 9 drug safety communication requiring labeling changes for GLP-1 receptor agonists, including Eli Lilly's Mounjaro and Zepbound and Novo Nordisk's Ozempic and Wegovy, to add warnings about non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause sudden, permanent vision loss in one eye. The FDA said it based the decision on clinical trial, animal and postmarket data, including observational studies and case reports. Novo Nordisk had already added a similar warning to European labels in June, but the warning had been absent from U.S. labels, and the American Academy of Ophthalmology previously said evidence did not support a blanket U.S. warning. The action comes as at least 4,000 consolidated claims allege GLP-1 drugs caused vision loss, and both drugmakers dispute a causal link.
- Federal Policy
CMS Requests Comment on Part D Pharmacy Contract Standards
CMS published a Sept. 24 Federal Register request for information asking what should count as "reasonable and relevant" terms in contracts between Medicare Part D plan sponsors and network pharmacies, a phrase CMS has never defined despite requiring it under existing rules. The request is a first step toward implementing a Consolidated Appropriations Act of 2026 provision requiring any willing pharmacy to participate in Part D networks starting with plan years on or after Jan. 1, 2029. CMS is seeking input on reimbursement and dispensing fees, specialty pharmacy designation, 340B contract terms, contract transparency, and quality/audit practices. Comments are due Nov. 23 under Docket CMS-2026-3037, a deadline the SBA's Office of Advocacy flagged to small businesses on Nov. 9.
- Federal Policy
CMS Delays Medicare Third-Party RPM Payment Ban to 2029
CMS finalized a two-year delay, to January 1, 2029, of a proposal ending Medicare payment for remote patient monitoring services provided by third-party vendors contracting with healthcare providers, according to Healthcare Dive. The original start date was January 1, 2027. CMS cited HHS Office of Inspector General findings that third-party contracting has led to fraud and improper billing, since billing providers may lack oversight of care delivered by outside vendors. Under the finalized policy, Medicare will eventually pay only for RPM services provided by clinical staff employed by the practice treating the patient. CMS also finalized a separate change limiting payment for monitoring of non-physiologic metrics, such as medication adherence and pain levels, to established patients. Virtual care lobbying groups including ATA Action and the Connected Health Initiative said they will use the two-year window to push CMS for program-integrity safeguards that preserve RPM access.

- Federal Policy
FDA Investigates Cancer Risk in Novartis's Zolgensma Gene Therapy
The FDA is investigating postmarket reports of malignancies, including confirmed cases of product-related insertional oncogenesis, in patients treated with Novartis's gene therapy Zolgensma for spinal muscular atrophy, according to a Nov. 6 agency safety communication. Reports include tumors of the central and peripheral nervous systems, spinal and paraspinal regions, and kidney; three cases involved the GLI1 oncogene, and in two the therapy's viral vector DNA had integrated near or within that gene. The FDA determined the risk applies to both onasemnogene abeparvovec products, Zolgensma (IV infusion for children under 2) and Itvisma (intrathecal injection for patients 2 and older), since they share the same vector and construct, though no neoplasia cases have been reported after Itvisma. The agency said overall benefits still outweigh risks for approved uses but is evaluating whether the product label and Novartis's long-term follow-up studies are adequate.
- Federal Policy
GAO Finds Broad Medicare, Medicaid Coverage of Overdose Reversal Drugs
GAO reports that all Medicare Part D and Medicaid enrollees had coverage of some form of naloxone in 2025 and 2024, respectively, while coverage of nalmefene, a newer and longer-acting overdose reversal medication, was less common. Part D out-of-pocket costs ranged from $3 to $10 median copays for generic naloxone injections up to 25 to 35 percent coinsurance for brand high-dose naloxone and nalmefene nasal sprays. Among four selected state Medicaid programs GAO reviewed, two had no copays and two had copays under $5. GAO analyzed 2025 Part D data and 2024 Medicaid drug reimbursement data from all 50 states and DC, and interviewed four plan sponsors and four state Medicaid programs about coverage and cost factors.
- Federal Policy
CMS Awards $10 Billion in Year Two Rural Health Transformation Funding
CMS announced $10 billion in second-year awards to all 50 states under the Rural Health Transformation Program, part of a five-year, $50 billion initiative created by the Working Families Tax Cuts Act. State FY2027 awards range from roughly $142 million to $282 million and were determined partly on states' progress implementing their approved transformation plans, including state policies such as the Presidential Fitness Test and physician continuing education on nutrition. States will use the funds to advance initiatives in their approved plans, including chronic disease prevention, workforce development, care and payment model innovation, and technology for rural providers. The program's five-year structure is intended to let states build, test, and scale approaches over time.
- Federal Policy
Georgetown CCF: Child SNAP Losses Outpace Medicaid/CHIP Enrollment Drops
Georgetown University's Center for Children and Families reports that child enrollment in Medicaid and CHIP fell by 2.56 million nationally from January 2025 through August 2026, based on state administrative data and CMS reporting. Drawing on Center on Budget and Policy Priorities tracking across 26 states, CCF finds child SNAP enrollment fell 15.7% (about 1.6 million children) from January 2025 to May 2026, compared to a 6.3% drop in Medicaid/CHIP enrollment in those same states, with the gap widening after H.R. 1's enactment in July 2025. CCF attributes the SNAP decline largely to H.R. 1 provisions already in effect, including tightened work reporting requirements and cuts to federal administrative funding, while noting Medicaid/CHIP's 12-month continuous eligibility requirement may be slowing similar losses there. CCF states children make up about 42% of those losing SNAP since July 2025 in tracked states.
- Federal Policy
KFF Experts: Election Results Raise Pressure to Reverse Medicaid Cuts
In a KFF webinar reported by Kansas Reflector, health policy experts discussed how Tuesday's Democratic election wins could shape healthcare policy. KFF's Larry Levitt said Democrats face high expectations to reverse Medicaid cuts from the One Big Beautiful Bill Act and restore ACA premium subsidies, but face a likely Trump veto and limited time before the 2028 election cycle slows Congress. Washington health policy reporter Amanda Seitz said Republicans view the Medicaid cuts as a signature achievement and doubted Trump would reverse them, but said rulemaking on Medicaid, including a court challenge to the definition of Medicaid frailty and work requirements set to take effect January 1, should be watched closely. KFF Health News' Julie Rovner noted Democrats have released an 84-page healthcare policy paper but questioned how they would pay for reversing roughly a trillion dollars in Medicaid cuts and hundreds of billions in ACA subsidy costs.

- Federal Policy · VT
Sanders Vows to Reverse Medicaid Cuts as Likely HELP Chair
Sen. Bernie Sanders, I-Vt., said he intends to reclaim the chairmanship of the Senate Health, Education, Labor and Pensions Committee after Tuesday's election put Democrats in control of both chambers of Congress. In an interview, Sanders said he would use the post to try to rescind provisions of the One Big Beautiful Bill Act that are slated to push millions of people off Medicaid, and to restore enhanced Affordable Care Act subsidies that lapsed last year. He also said he wants the committee to "be very aggressive about moving toward 'Medicare for All'," remarks he made Thursday. Democrats were projected as of Friday to control at least 54 Senate seats and 253 House seats, with some races still uncalled.

Friday, November 6 · 6 stories
- Federal Policy
SHVS Analyzes CMS, IRS Proposed Rules on ACA Verification Rules
In a resource analyzing two federal proposed rules, State Health and Value Strategies (SHVS) reports that the IRS released a proposed rule on October 15 and CMS released a proposed rule on October 27 to implement premium tax credit and eligibility verification changes required by the 2025 budget reconciliation law (H.R. 1). SHVS states the CMS rule would end automatic re-enrollment for subsidized Marketplace consumers, require manual re-enrollment each year, and deny subsidies while eligibility is being verified, creating months-long waits for some consumers. The analysis says these changes would impose substantial new administrative burdens on State-Based Marketplaces, which would need to rebuild eligibility and enrollment systems, and notes the new requirements have an August 1, 2027 go-live date that SHVS says the rule is unlikely to be finalized in time to meet. SHVS also notes mitigation provisions, including an extended verification period, pended enrollment, and retroactive financial assistance, but says these may be complex or unworkable.
- Federal Policy
Democrats’ midterm landslide spells relief for hospitals